Cargando…
Peripheral Glycolysis in Neurodegenerative Diseases
Neurodegenerative diseases are a group of nervous system conditions characterised pathologically by the abnormal deposition of protein throughout the brain and spinal cord. One common pathophysiological change seen in all neurodegenerative disease is a change to the metabolic function of nervous sys...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727792/ https://www.ncbi.nlm.nih.gov/pubmed/33255513 http://dx.doi.org/10.3390/ijms21238924 |
_version_ | 1783621130353901568 |
---|---|
author | Bell, Simon M. Burgess, Toby Lee, James Blackburn, Daniel J. Allen, Scott P. Mortiboys, Heather |
author_facet | Bell, Simon M. Burgess, Toby Lee, James Blackburn, Daniel J. Allen, Scott P. Mortiboys, Heather |
author_sort | Bell, Simon M. |
collection | PubMed |
description | Neurodegenerative diseases are a group of nervous system conditions characterised pathologically by the abnormal deposition of protein throughout the brain and spinal cord. One common pathophysiological change seen in all neurodegenerative disease is a change to the metabolic function of nervous system and peripheral cells. Glycolysis is the conversion of glucose to pyruvate or lactate which results in the generation of ATP and has been shown to be abnormal in peripheral cells in Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis. Changes to the glycolytic pathway are seen early in neurodegenerative disease and highlight how in multiple neurodegenerative conditions pathology is not always confined to the nervous system. In this paper, we review the abnormalities described in glycolysis in the three most common neurodegenerative diseases. We show that in all three diseases glycolytic changes are seen in fibroblasts, and red blood cells, and that liver, kidney, muscle and white blood cells have abnormal glycolysis in certain diseases. We highlight there is potential for peripheral glycolysis to be developed into multiple types of disease biomarker, but large-scale bio sampling and deciphering how glycolysis is inherently altered in neurodegenerative disease in multiple patients’ needs to be accomplished first to meet this aim. |
format | Online Article Text |
id | pubmed-7727792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77277922020-12-11 Peripheral Glycolysis in Neurodegenerative Diseases Bell, Simon M. Burgess, Toby Lee, James Blackburn, Daniel J. Allen, Scott P. Mortiboys, Heather Int J Mol Sci Review Neurodegenerative diseases are a group of nervous system conditions characterised pathologically by the abnormal deposition of protein throughout the brain and spinal cord. One common pathophysiological change seen in all neurodegenerative disease is a change to the metabolic function of nervous system and peripheral cells. Glycolysis is the conversion of glucose to pyruvate or lactate which results in the generation of ATP and has been shown to be abnormal in peripheral cells in Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis. Changes to the glycolytic pathway are seen early in neurodegenerative disease and highlight how in multiple neurodegenerative conditions pathology is not always confined to the nervous system. In this paper, we review the abnormalities described in glycolysis in the three most common neurodegenerative diseases. We show that in all three diseases glycolytic changes are seen in fibroblasts, and red blood cells, and that liver, kidney, muscle and white blood cells have abnormal glycolysis in certain diseases. We highlight there is potential for peripheral glycolysis to be developed into multiple types of disease biomarker, but large-scale bio sampling and deciphering how glycolysis is inherently altered in neurodegenerative disease in multiple patients’ needs to be accomplished first to meet this aim. MDPI 2020-11-24 /pmc/articles/PMC7727792/ /pubmed/33255513 http://dx.doi.org/10.3390/ijms21238924 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bell, Simon M. Burgess, Toby Lee, James Blackburn, Daniel J. Allen, Scott P. Mortiboys, Heather Peripheral Glycolysis in Neurodegenerative Diseases |
title | Peripheral Glycolysis in Neurodegenerative Diseases |
title_full | Peripheral Glycolysis in Neurodegenerative Diseases |
title_fullStr | Peripheral Glycolysis in Neurodegenerative Diseases |
title_full_unstemmed | Peripheral Glycolysis in Neurodegenerative Diseases |
title_short | Peripheral Glycolysis in Neurodegenerative Diseases |
title_sort | peripheral glycolysis in neurodegenerative diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727792/ https://www.ncbi.nlm.nih.gov/pubmed/33255513 http://dx.doi.org/10.3390/ijms21238924 |
work_keys_str_mv | AT bellsimonm peripheralglycolysisinneurodegenerativediseases AT burgesstoby peripheralglycolysisinneurodegenerativediseases AT leejames peripheralglycolysisinneurodegenerativediseases AT blackburndanielj peripheralglycolysisinneurodegenerativediseases AT allenscottp peripheralglycolysisinneurodegenerativediseases AT mortiboysheather peripheralglycolysisinneurodegenerativediseases |